Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occ...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: van Acker, S. A., Kramer, K., Grimbergen, J. A., van den Berg, D. J., van der Vijgh, W. J., Bast, A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 1995
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1908788/
https://ncbi.nlm.nih.gov/pubmed/7582554
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky